Health Sciences Acquisitions Corporation 2
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HSAQ research report →
Price Chart
About the company
Health Sciences Acquisitions Corporation 2 currently lacks active business operations. Its primary objective is to complete a strategic business combination, such as a merger or acquisition, with one or more enterprises. These target businesses will operate within the biopharmaceutical or medical technology sectors and be located in North America or Europe.
- CEO
- Roderick Tze Ian Wong
- IPO
- 2020
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on HSAQ
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $149.23M
- P/E
- -7.39
- PEG
- -0.09
- P/S
- 16.60
- P/B
- 22.68
- EV/EBITDA
- -10.73
- Div Yield
- 0.00%
- Gross Margin
- 99.37%
- Op Margin
- -195.39%
- Net Margin
- -182.50%
- ROE
- -140.18%
- ROIC
- -64.63%
Latest fiscal year · YoY change
- Revenue
- $33.48M+1169.2%
- Gross Profit
- $33.29M+1267.8%
- Op Income
- $-51,807,000
- Net Income
- $-52,955,000+13.2%
- EPS
- $-1.11+33.1%
- OCF Growth
- +3.2%
- FCF Growth
- +2.7%
- 52W High
- $13.80
- 52W Low
- $9.41
- 50D MA
- $10.06
- 200D MA
- $9.96
- Beta
- 0.00
- RSI (14)
- 97
- Avg Volume
- 71.38K
No earnings-call transcripts are available for HSAQ yet.
- Free Float
- 0.0%
- Shares Outstanding
- 11.21M
- Float Shares
- 0
of shares held by institutions
23 13F filers
Buy/sell ratio 1.13. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Spring Creek Capital LLC | 46.39K | ▲ 46.39K |
| Lenox Wealth Advisors, LLC | 2.00K | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 19, 23 | Papandreou George | other | 0 |
| Sep 19, 23 | Papandreou George | other | 0 |
| Sep 19, 23 | Papandreou George | other | 0 |
| Sep 19, 23 | Papandreou George | other | 0 |
| Sep 19, 23 | Papandreou George | other | 0 |
| Sep 19, 23 | Papandreou George | other | 0 |
| Jul 20, 23 | Smith Geoffrey Wade | other | 16,667 |
| Jul 20, 23 | Aryeh Jason | other | 25,000 |
| Jul 20, 23 | Hochman David P | other | 300,000 |
| Jul 20, 23 | Hochman David P | other | 165,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our HSAQ coverage
Recent articles, reports, and earnings notes.
No research on HSAQ yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HSAQ report →Defiance Daily Target 2X Long LMND ETF (NASDAQ:LMNX) & Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) Critical Comparison
defenseworld.net · Apr 21
Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) Trading Up 1.3% – Here’s What Happened
defenseworld.net · Mar 19
Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) Shares Down 2.9% – Should You Sell?
defenseworld.net · Jan 14
Comparing Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) & INVO Fertility (NASDAQ:IVF)
defenseworld.net · Dec 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.